Following a partnership with a Singapore
company, the Pharmaceutical Industry Technology Development Center (PTC) today
(8 August) announced that it has entered into a partnership with PT. Sel
Regenerasi Biotek signed a letter of intent to collaborate on the development
of cell therapy products for infectious diseases, and the company will soon set
up a subsidiary in Taiwan, and in the future, it will bridge with Taiwan's
regenerative medicine CDMO manufacturers through the Pharmaceutical Technology
Center.
PT. Sel Regenerasi Biotek, a company
focused on biologic cell medical and biotechnology research, has partnered and looking
an opportunity with Indonesia's National Center for Infectious Diseases
Hospital to conduct clinical trials of
cellular medical and stem cell exosomes for the treatment of post-tuberculosis
sequelae.
According to the Pharmaceutical Technology
Center, through the subsidy program of the Department of Industrial Technology
of the Ministry of Economic Affairs, it has successfully established a series
of regenerative medicine technologies such as cell culture medium formulation
optimization platform, precision immunomodulation, and neural repair stem cell
process, which has become a basis for attracting international cooperation, and
after signing a cooperation agreement with Singapore's ECCO Group, it has once
again attracted ASEAN countries to sign a memorandum of cooperation to
cooperate in the development of regenerative medicine technology products.
ASEAN countries are seen as the next
fast-growing region, and Indonesia is the largest economy in ASEAN, with a
population of 270 million, making it a medical market with huge growth
potential. This cooperation project is expected to inject another breath of
fresh water into Taiwan's emerging cell therapy industry chain, become a
stepping stone to enter the ASEAN market, and open up a new development space
for the regenerative medicine field of the two countries and even ASEAN
countries.
In response to the cooperation between the
two parties, PT. Bintarna Tardy, chairman of Sel Regenerasi Biotek, said that
in the near future, a subsidiary will be set up in Taiwan, and the advanced
process of stem cells and exosomes will be introduced in cooperation with the
Pharmaceutical Technology Center, and the CDMO energy will be produced with the
help of cells in Taiwan to accelerate the process of clinical trials.
The Pharmaceutical Technology Center noted
that it will assist PT. Sel Regenerasi Biotek has set up a subsidiary in Taiwan
to prepare pre-clinical (pre-IND) data for cell preparations, and assist in
bridging CDMO companies in domestic cell production, expanding international
business opportunities for domestic cell manufacturers and opening up new blue
ocean markets in Southeast Asia.